Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (700)	2/18/1998 11:01:00 PM
From: David Cathcart	Read Replies (2) \| Respond to of 1826

Bear, << One thing I am still trying to understand better is the size/profitability of the Salagen market. Just how large is it, really? (I have read extremely wide-ranging estimates that primary Sjogren's is from $30 million annually, and up.)>> Good luck. :-) It's the big question and the one no one seems to be able to pin down an answer to. The company was of little help in the conference call. They said something to the effect that the Sjogren's market would be at least as big as head & neck. I think they were ambiguous for two reasons. First, they are gun shy after the letdown from head & neck. Second, there are widely varying estimates as to how big the Sjogren's market is. However, even if you are conservative and target $25 million, you will still profit nicely and be onboard to see if tumors shrink. You may not want to load up on this stock the way RDB and I have, but there seems to be virtually no downside risk and untold upside potential. If Salagen sales take off, you'll wish you had loaded up. Once the European deal is complete, you'll wish you had loaded up. If tumors start shrinking, you'll wish you had taken out a second mortgage. David